




## RESEARCH HIGHLIGHTS




### Neural network stuns with accuracy in targeting patients who will benefit from treatment

By analyzing quantitative ultrasound images, a new artificial neural network can predict who will benefit from neoadjuvant chemotherapy with stunning accuracy.




### First-of-its-kind proteogenomic resource provides key insights into the biology of prostate cancers

The resource combines genomic, epigenomic, transcriptomic and proteomic data from localized, intermediate-risk prostate cancers and sheds light on the proteogenomic underpinnings of cancer.



### Toronto-based team identifies potential target to suppress leukemia stem cells, avoid relapse

Targeting a gene called INKA1 may suppress leukemia stem cells (LSCs), stopping the disease in its tracks or preventing relapse in patients who have already undergone treatment.



### New finding uncovers how neuroendocrine prostate cancer progresses

Team reveals how RNA splicing of BHC80 promotes the development of treatment-induced neuroendocrine prostate cancer, providing potential avenues for future tests and treatments.



### Silencing TP73/p73 could prevent cancer stem-like cells from regenerating after treatment

Discovery provides key insights into the mechanisms used by brain cancer cells to elude treatment and finds a new target that could be exploited to disrupt them.




### Pan-Canadian team identifies two biomarkers that predict prostate cancer aggressiveness

The discoveries that the proteins p65 and CCN3 indicate cancer aggressiveness could help bridge a major gap that still exists in prostate cancer research: patient stratification.



### Results from two studies provide insight into who may benefit from immunotherapies

Two published papers partially funded by the TFRI are starting to paint a clearer picture of who may benefit from the use of immune checkpoint inhibitors, bridging a major gap in immunotherapy research.



### How a TFRI-funded team is harnessing the power of light to improve cancer care

Eight years ago, researchers looking to improve how cancer is diagnosed and treated decided to develop a nanoparticle that mimicked how natural organisms harvest light. Now, their porphyrinsomes are ready for human trials.

## TFRI NEWS

An update from our President

TFRI will host special session on Marathon of Hope Cancer Centres Network at 5th CCRC meeting

TFRI presents its new poster and presentation templates for researchers

Terry Fox PROFYLE is giving hope to children and young adults previously out of treatment options

2019 Terry Fox Run Challenge: TFRI Research team show immense support, raise nearly \$80k for research

Survivor hails investment in new TFRI-led artificial intelligence platform to accelerate precision medicine for cancer

Links is compiled and circulated quarterly by TFRI to highlight recently published research by our funded investigators. It is produced by TFRI HQ in Vancouver, BC. TFRI is either the principal or supporting funder of the research presented here. We hope you enjoyed reading this issue. Please send any questions or feedback to: [links@tfri.ca](mailto:links@tfri.ca)

Previous issues are available online in our [E-Newsletter Archive](#).

Visit [www.tfri.ca](http://www.tfri.ca) to learn more about our research investment portfolio

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.

